蟾酥注射液联合同步放化疗治疗局部晚期胰腺癌的临床研究

Clinical observation on treating advanced pancreatic cancer with Chansu injection plus the concurrent chemoradiotherapy

目的:探讨蟾酥注射液联合同步放化疗治疗局部晚期胰腺癌的疗效和毒性反应。方法:2010年1月-2012年5月共收治局部晚期胰腺癌患者28例,实验组17例采用蟾酥注射液联合同步放化疗治疗;对照组仅采用同步放化疗。放疗采用调强适形放疗(IMRT),DT:50~60Gy;同步化疗方案为:吉西他滨1000mg,dl,d8,d15。四周重复与放疗同步,放疗结束后行同方案化疗,共4~6周期。结果:所有患者均完成同步放化治疗。治疗组有效率为76.5%,对照组有效率为72.7%,两组比较无统计学差异(P>0.05);毒副作用主要是骨髓抑制和胃肠道反应,骨髓抑制和胃肠道反应I^IV比较有统计学差异(P<0.05),肝肾功能损伤I^IV比较无统计学差异(P>0.05)。结论:蟾酥注射液联合同步放化疗治疗局部晚期胰腺癌疗效显著,能够缓解同步放化疗毒副反应。

Objective： To explore the curative effect and toxic reaction of toad venom injection combined with the concurrent chemoradiotherapy for locally advanced pancreatic cancer. Methods： 28 patients were treated, 17 patients were treated with Chansu injection injection combined with the concurrent chemoradiotherapy; 11 patients were treated with the concurrent chemoradiotherapy. The concurrent chemoradiotherapy was IMRT （DT：50-60gGy）, gemcitabine 1000mg （dl,d8,d15）, 28 days in each cycle. After CCRT, 2-4 cycles of the same program for consolidation chemotherapy were used 1 month later. Results： No patients were excluded. The total efficacy in the trial group and the control group were 76.5% and 72.7%, respectively （P〉0.05）; toxic reaction in trial group was lower than the control group with I-IVarrest of bone marrow and gastrointestinal reaction （P〉0.05）, liver and kidney function damage was no different between trial group and the control group. Conclusion： Toad venom injection combined with the concurrent chradiotherapy for advanced pancreatic carcinoma are effective well tolerated in patients.